Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) EPS (Weighted Average and Diluted) (2016 - 2025)

Protalix BioTherapeutics (PLX) has 13 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.04 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 33.33% year-over-year to $0.04; the TTM value through Sep 2025 reached $0.08, up 161.54%, while the annual FY2024 figure was $0.04, 55.56% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.04 in Q3 2025 per PLX's latest filing, up from -$0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.21 in Q2 2023 and bottomed at -$0.25 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.05, with a median of -$0.06 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 566.67% in 2021, then surged 290.91% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.14 in 2021, then surged by 50.0% to -$0.07 in 2022, then changed by 0.0% to -$0.07 in 2023, then soared by 228.57% to $0.09 in 2024, then crashed by 55.56% to $0.04 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.04 in Q3 2025, -$0.05 in Q1 2025, and $0.09 in Q4 2024.